Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer
BACKGROUND: Lung cancer is the leading cause of cancer death in the world. The objective of this study was to investigate the expression of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in patients with nonsmall cell lung cancer (NSCLC) and its correlation with the prognos...
Gespeichert in:
| Veröffentlicht in: | Cancer 2009-04, Vol.115 (8), p.1701-1712 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1712 |
|---|---|
| container_issue | 8 |
| container_start_page | 1701 |
| container_title | Cancer |
| container_volume | 115 |
| creator | Carrillo de Santa Pau, Enrique Arias, Fernando Carrillo Caso Peláez, Enrique Muñoz Molina, Gemma María Sánchez Hernández, Ignacio Muguruza Trueba, Ignacio Moreno Balsalobre, Ramón Sacristán López, Silvia Gómez Pinillos, Alejandro del Val Toledo Lobo, María |
| description | BACKGROUND:
Lung cancer is the leading cause of cancer death in the world. The objective of this study was to investigate the expression of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in patients with nonsmall cell lung cancer (NSCLC) and its correlation with the prognosis for patients with lung cancer.
METHODS:
The expression status of VEGFs and VEGFRs was examined in 48 nonconsecutive specimens of primary lung cancer by immunohistochemistry. Correlations between the expression of VEGFs and VEGFRs and clinicopathologic parameters were analyzed.
RESULTS:
Nineteen of 48 samples (39.6%) were moderately/highly immunoreactive for VEGF‐A, 6 samples (12.5%) were reactive for VEGF‐B, 14 samples (29.2%) were reactive for VEGF‐C, 11 samples (22.9%) were reactive for VEGF‐D, 20 samples (41.7%) were reactive for VEGFR1, 26 samples (54.2%) were reactive for VEGFR2, 20 samples (41.7%) were reactive for VEGFR3, and 19 samples (39.6%) were reactive for nuclear expression of VEGFR3. Patients with moderate/high VEGF‐C, VEGFR1, and VEGFR2 expression had worse survival, whereas patients with moderate/high VEGF‐D and nuclear VEGFR3 expression had better survival. After adjusting according to tumor stage, VEGF‐B and VEGF‐D expression had a significant correlation with worse survival in patients with stage I and II disease. Patients with stage III and IV disease who had VEGFR1 and VEGFR2 expression had worse survival, whereas the expression of VEGF‐D was correlated significantly with better survival. Finally, stage, VEGF‐D expression, and VEGFR1 expression were significantly independent prognostic predictors.
CONCLUSIONS:
The results of the current study indicated that the over‐expression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC. The inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC. Cancer 2009. © 2009 American Cancer Society.
The authors analyzed expression of the vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) family of proteins and survival in patients with nonsmall cell lung cancer (NSCLC). The results indicated that the overexpression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC, and the inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC. |
| doi_str_mv | 10.1002/cncr.24193 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67118909</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67118909</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3933-c9f9615c462cb34805f51e85dc7a9add10f0f8baa964778fe1d9e16145cc7e93</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EotPChgdAZwOLalJ84ty8LOEqVYBGXbCLPI49NfLYqZ0w9KF4R5zJCHZsjuVzPv3n8hPyAukVUpq_kU6Gq7xAzh6RFVJeZxSL_DFZUUqbrCzY9zNyHuOP9K3zkj0lZ8iR15w3K_L7W_A75-NoJESzc0YbKZxU4DWMdwrUryGoGI13c-aniHKyIoByvU9la4SFXfCH8Q60kKMPEa7X8HYN7RqE6-HdMSbSBAhKquGIbHANm3whNgyMg0GMRrkxwsEkKedd3AtrQaoU7OR2cBwqPCNPtLBRPT-9F-T2w_vb9lN28_Xj5_b6JpOMM5ZJrnmFpSyqXG5Z0dBSl6iaspe14KLvkWqqm60QvCrqutEKe66wwqKUslacXZDXi-wQ_P2k4tjtTZxnEU75KXZVjdhwOoOXCyiDjzEo3Q3B7EV46JB2szfd7E139CbBL0-q03av-n_oyYwEvDoB6czC6pB2NvEvlyPDKq2VOFy4g7Hq4T8tu_ZLu1ma_wGegKe1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67118909</pqid></control><display><type>article</type><title>Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Carrillo de Santa Pau, Enrique ; Arias, Fernando Carrillo ; Caso Peláez, Enrique ; Muñoz Molina, Gemma María ; Sánchez Hernández, Ignacio ; Muguruza Trueba, Ignacio ; Moreno Balsalobre, Ramón ; Sacristán López, Silvia ; Gómez Pinillos, Alejandro ; del Val Toledo Lobo, María</creator><creatorcontrib>Carrillo de Santa Pau, Enrique ; Arias, Fernando Carrillo ; Caso Peláez, Enrique ; Muñoz Molina, Gemma María ; Sánchez Hernández, Ignacio ; Muguruza Trueba, Ignacio ; Moreno Balsalobre, Ramón ; Sacristán López, Silvia ; Gómez Pinillos, Alejandro ; del Val Toledo Lobo, María</creatorcontrib><description>BACKGROUND:
Lung cancer is the leading cause of cancer death in the world. The objective of this study was to investigate the expression of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in patients with nonsmall cell lung cancer (NSCLC) and its correlation with the prognosis for patients with lung cancer.
METHODS:
The expression status of VEGFs and VEGFRs was examined in 48 nonconsecutive specimens of primary lung cancer by immunohistochemistry. Correlations between the expression of VEGFs and VEGFRs and clinicopathologic parameters were analyzed.
RESULTS:
Nineteen of 48 samples (39.6%) were moderately/highly immunoreactive for VEGF‐A, 6 samples (12.5%) were reactive for VEGF‐B, 14 samples (29.2%) were reactive for VEGF‐C, 11 samples (22.9%) were reactive for VEGF‐D, 20 samples (41.7%) were reactive for VEGFR1, 26 samples (54.2%) were reactive for VEGFR2, 20 samples (41.7%) were reactive for VEGFR3, and 19 samples (39.6%) were reactive for nuclear expression of VEGFR3. Patients with moderate/high VEGF‐C, VEGFR1, and VEGFR2 expression had worse survival, whereas patients with moderate/high VEGF‐D and nuclear VEGFR3 expression had better survival. After adjusting according to tumor stage, VEGF‐B and VEGF‐D expression had a significant correlation with worse survival in patients with stage I and II disease. Patients with stage III and IV disease who had VEGFR1 and VEGFR2 expression had worse survival, whereas the expression of VEGF‐D was correlated significantly with better survival. Finally, stage, VEGF‐D expression, and VEGFR1 expression were significantly independent prognostic predictors.
CONCLUSIONS:
The results of the current study indicated that the over‐expression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC. The inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC. Cancer 2009. © 2009 American Cancer Society.
The authors analyzed expression of the vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) family of proteins and survival in patients with nonsmall cell lung cancer (NSCLC). The results indicated that the overexpression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC, and the inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.24193</identifier><identifier>PMID: 19197998</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; Aged, 80 and over ; angiogenesis‐inducing agents ; Biological and medical sciences ; Female ; Humans ; Immunohistochemistry ; lung neoplasms ; Lung Neoplasms - metabolism ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Prognosis ; Receptors, Growth Factor - metabolism ; Small Cell Lung Carcinoma - metabolism ; Small Cell Lung Carcinoma - mortality ; Small Cell Lung Carcinoma - pathology ; survival analysis ; Tumors ; Tumors of the respiratory system and mediastinum ; vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - metabolism ; Vascular Endothelial Growth Factor B - metabolism ; Vascular Endothelial Growth Factor C - metabolism ; Vascular Endothelial Growth Factor D - metabolism ; Vascular Endothelial Growth Factor Receptor-1 - genetics ; Vascular Endothelial Growth Factor Receptor-2 - metabolism ; Vascular Endothelial Growth Factor Receptor-3 - genetics ; vascular endothelial growth factor receptors ; Vascular Endothelial Growth Factors - metabolism</subject><ispartof>Cancer, 2009-04, Vol.115 (8), p.1701-1712</ispartof><rights>Copyright © 2009 American Cancer Society</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3933-c9f9615c462cb34805f51e85dc7a9add10f0f8baa964778fe1d9e16145cc7e93</citedby><cites>FETCH-LOGICAL-c3933-c9f9615c462cb34805f51e85dc7a9add10f0f8baa964778fe1d9e16145cc7e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.24193$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.24193$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21316615$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19197998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carrillo de Santa Pau, Enrique</creatorcontrib><creatorcontrib>Arias, Fernando Carrillo</creatorcontrib><creatorcontrib>Caso Peláez, Enrique</creatorcontrib><creatorcontrib>Muñoz Molina, Gemma María</creatorcontrib><creatorcontrib>Sánchez Hernández, Ignacio</creatorcontrib><creatorcontrib>Muguruza Trueba, Ignacio</creatorcontrib><creatorcontrib>Moreno Balsalobre, Ramón</creatorcontrib><creatorcontrib>Sacristán López, Silvia</creatorcontrib><creatorcontrib>Gómez Pinillos, Alejandro</creatorcontrib><creatorcontrib>del Val Toledo Lobo, María</creatorcontrib><title>Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND:
Lung cancer is the leading cause of cancer death in the world. The objective of this study was to investigate the expression of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in patients with nonsmall cell lung cancer (NSCLC) and its correlation with the prognosis for patients with lung cancer.
METHODS:
The expression status of VEGFs and VEGFRs was examined in 48 nonconsecutive specimens of primary lung cancer by immunohistochemistry. Correlations between the expression of VEGFs and VEGFRs and clinicopathologic parameters were analyzed.
RESULTS:
Nineteen of 48 samples (39.6%) were moderately/highly immunoreactive for VEGF‐A, 6 samples (12.5%) were reactive for VEGF‐B, 14 samples (29.2%) were reactive for VEGF‐C, 11 samples (22.9%) were reactive for VEGF‐D, 20 samples (41.7%) were reactive for VEGFR1, 26 samples (54.2%) were reactive for VEGFR2, 20 samples (41.7%) were reactive for VEGFR3, and 19 samples (39.6%) were reactive for nuclear expression of VEGFR3. Patients with moderate/high VEGF‐C, VEGFR1, and VEGFR2 expression had worse survival, whereas patients with moderate/high VEGF‐D and nuclear VEGFR3 expression had better survival. After adjusting according to tumor stage, VEGF‐B and VEGF‐D expression had a significant correlation with worse survival in patients with stage I and II disease. Patients with stage III and IV disease who had VEGFR1 and VEGFR2 expression had worse survival, whereas the expression of VEGF‐D was correlated significantly with better survival. Finally, stage, VEGF‐D expression, and VEGFR1 expression were significantly independent prognostic predictors.
CONCLUSIONS:
The results of the current study indicated that the over‐expression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC. The inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC. Cancer 2009. © 2009 American Cancer Society.
The authors analyzed expression of the vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) family of proteins and survival in patients with nonsmall cell lung cancer (NSCLC). The results indicated that the overexpression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC, and the inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>angiogenesis‐inducing agents</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>lung neoplasms</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Receptors, Growth Factor - metabolism</subject><subject>Small Cell Lung Carcinoma - metabolism</subject><subject>Small Cell Lung Carcinoma - mortality</subject><subject>Small Cell Lung Carcinoma - pathology</subject><subject>survival analysis</subject><subject>Tumors</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vascular Endothelial Growth Factor B - metabolism</subject><subject>Vascular Endothelial Growth Factor C - metabolism</subject><subject>Vascular Endothelial Growth Factor D - metabolism</subject><subject>Vascular Endothelial Growth Factor Receptor-1 - genetics</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - metabolism</subject><subject>Vascular Endothelial Growth Factor Receptor-3 - genetics</subject><subject>vascular endothelial growth factor receptors</subject><subject>Vascular Endothelial Growth Factors - metabolism</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0EotPChgdAZwOLalJ84ty8LOEqVYBGXbCLPI49NfLYqZ0w9KF4R5zJCHZsjuVzPv3n8hPyAukVUpq_kU6Gq7xAzh6RFVJeZxSL_DFZUUqbrCzY9zNyHuOP9K3zkj0lZ8iR15w3K_L7W_A75-NoJESzc0YbKZxU4DWMdwrUryGoGI13c-aniHKyIoByvU9la4SFXfCH8Q60kKMPEa7X8HYN7RqE6-HdMSbSBAhKquGIbHANm3whNgyMg0GMRrkxwsEkKedd3AtrQaoU7OR2cBwqPCNPtLBRPT-9F-T2w_vb9lN28_Xj5_b6JpOMM5ZJrnmFpSyqXG5Z0dBSl6iaspe14KLvkWqqm60QvCrqutEKe66wwqKUslacXZDXi-wQ_P2k4tjtTZxnEU75KXZVjdhwOoOXCyiDjzEo3Q3B7EV46JB2szfd7E139CbBL0-q03av-n_oyYwEvDoB6czC6pB2NvEvlyPDKq2VOFy4g7Hq4T8tu_ZLu1ma_wGegKe1</recordid><startdate>20090415</startdate><enddate>20090415</enddate><creator>Carrillo de Santa Pau, Enrique</creator><creator>Arias, Fernando Carrillo</creator><creator>Caso Peláez, Enrique</creator><creator>Muñoz Molina, Gemma María</creator><creator>Sánchez Hernández, Ignacio</creator><creator>Muguruza Trueba, Ignacio</creator><creator>Moreno Balsalobre, Ramón</creator><creator>Sacristán López, Silvia</creator><creator>Gómez Pinillos, Alejandro</creator><creator>del Val Toledo Lobo, María</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090415</creationdate><title>Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer</title><author>Carrillo de Santa Pau, Enrique ; Arias, Fernando Carrillo ; Caso Peláez, Enrique ; Muñoz Molina, Gemma María ; Sánchez Hernández, Ignacio ; Muguruza Trueba, Ignacio ; Moreno Balsalobre, Ramón ; Sacristán López, Silvia ; Gómez Pinillos, Alejandro ; del Val Toledo Lobo, María</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3933-c9f9615c462cb34805f51e85dc7a9add10f0f8baa964778fe1d9e16145cc7e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>angiogenesis‐inducing agents</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>lung neoplasms</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Receptors, Growth Factor - metabolism</topic><topic>Small Cell Lung Carcinoma - metabolism</topic><topic>Small Cell Lung Carcinoma - mortality</topic><topic>Small Cell Lung Carcinoma - pathology</topic><topic>survival analysis</topic><topic>Tumors</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vascular Endothelial Growth Factor B - metabolism</topic><topic>Vascular Endothelial Growth Factor C - metabolism</topic><topic>Vascular Endothelial Growth Factor D - metabolism</topic><topic>Vascular Endothelial Growth Factor Receptor-1 - genetics</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - metabolism</topic><topic>Vascular Endothelial Growth Factor Receptor-3 - genetics</topic><topic>vascular endothelial growth factor receptors</topic><topic>Vascular Endothelial Growth Factors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carrillo de Santa Pau, Enrique</creatorcontrib><creatorcontrib>Arias, Fernando Carrillo</creatorcontrib><creatorcontrib>Caso Peláez, Enrique</creatorcontrib><creatorcontrib>Muñoz Molina, Gemma María</creatorcontrib><creatorcontrib>Sánchez Hernández, Ignacio</creatorcontrib><creatorcontrib>Muguruza Trueba, Ignacio</creatorcontrib><creatorcontrib>Moreno Balsalobre, Ramón</creatorcontrib><creatorcontrib>Sacristán López, Silvia</creatorcontrib><creatorcontrib>Gómez Pinillos, Alejandro</creatorcontrib><creatorcontrib>del Val Toledo Lobo, María</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carrillo de Santa Pau, Enrique</au><au>Arias, Fernando Carrillo</au><au>Caso Peláez, Enrique</au><au>Muñoz Molina, Gemma María</au><au>Sánchez Hernández, Ignacio</au><au>Muguruza Trueba, Ignacio</au><au>Moreno Balsalobre, Ramón</au><au>Sacristán López, Silvia</au><au>Gómez Pinillos, Alejandro</au><au>del Val Toledo Lobo, María</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2009-04-15</date><risdate>2009</risdate><volume>115</volume><issue>8</issue><spage>1701</spage><epage>1712</epage><pages>1701-1712</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND:
Lung cancer is the leading cause of cancer death in the world. The objective of this study was to investigate the expression of vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) in patients with nonsmall cell lung cancer (NSCLC) and its correlation with the prognosis for patients with lung cancer.
METHODS:
The expression status of VEGFs and VEGFRs was examined in 48 nonconsecutive specimens of primary lung cancer by immunohistochemistry. Correlations between the expression of VEGFs and VEGFRs and clinicopathologic parameters were analyzed.
RESULTS:
Nineteen of 48 samples (39.6%) were moderately/highly immunoreactive for VEGF‐A, 6 samples (12.5%) were reactive for VEGF‐B, 14 samples (29.2%) were reactive for VEGF‐C, 11 samples (22.9%) were reactive for VEGF‐D, 20 samples (41.7%) were reactive for VEGFR1, 26 samples (54.2%) were reactive for VEGFR2, 20 samples (41.7%) were reactive for VEGFR3, and 19 samples (39.6%) were reactive for nuclear expression of VEGFR3. Patients with moderate/high VEGF‐C, VEGFR1, and VEGFR2 expression had worse survival, whereas patients with moderate/high VEGF‐D and nuclear VEGFR3 expression had better survival. After adjusting according to tumor stage, VEGF‐B and VEGF‐D expression had a significant correlation with worse survival in patients with stage I and II disease. Patients with stage III and IV disease who had VEGFR1 and VEGFR2 expression had worse survival, whereas the expression of VEGF‐D was correlated significantly with better survival. Finally, stage, VEGF‐D expression, and VEGFR1 expression were significantly independent prognostic predictors.
CONCLUSIONS:
The results of the current study indicated that the over‐expression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC. The inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC. Cancer 2009. © 2009 American Cancer Society.
The authors analyzed expression of the vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) family of proteins and survival in patients with nonsmall cell lung cancer (NSCLC). The results indicated that the overexpression of VEGFs and VEGFRs plays an important role in the survival of patients with NSCLC, and the inclusion of angiogenic factors in the standard pathologic study of lung cancer may improve the clinical evaluation of patients with NSCLC.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>19197998</pmid><doi>10.1002/cncr.24193</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2009-04, Vol.115 (8), p.1701-1712 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67118909 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over angiogenesis‐inducing agents Biological and medical sciences Female Humans Immunohistochemistry lung neoplasms Lung Neoplasms - metabolism Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medical sciences Middle Aged Pneumology Prognosis Receptors, Growth Factor - metabolism Small Cell Lung Carcinoma - metabolism Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - pathology survival analysis Tumors Tumors of the respiratory system and mediastinum vascular endothelial growth factor Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor B - metabolism Vascular Endothelial Growth Factor C - metabolism Vascular Endothelial Growth Factor D - metabolism Vascular Endothelial Growth Factor Receptor-1 - genetics Vascular Endothelial Growth Factor Receptor-2 - metabolism Vascular Endothelial Growth Factor Receptor-3 - genetics vascular endothelial growth factor receptors Vascular Endothelial Growth Factors - metabolism |
| title | Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T08%3A56%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20the%20expression%20of%20vascular%20endothelial%20growth%20factors%20A,%20B,%20C,%20and%20D%20and%20their%20receptors%20R1,%20R2,%20and%20R3%20in%20patients%20with%20nonsmall%20cell%20lung%20cancer&rft.jtitle=Cancer&rft.au=Carrillo%20de%20Santa%20Pau,%20Enrique&rft.date=2009-04-15&rft.volume=115&rft.issue=8&rft.spage=1701&rft.epage=1712&rft.pages=1701-1712&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.24193&rft_dat=%3Cproquest_cross%3E67118909%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67118909&rft_id=info:pmid/19197998&rfr_iscdi=true |